Project Grant R56HL172052
Award Date
9/20/24
Completion Date
8/31/25
Dollars Obligated
$642K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
College Station, TX 77843, USA
Similar Awards
This $102,932 Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to identify clinically accessible metrics that can serve as surrogates for right ventricular-pulmonary arterial (RV-PA) coupling and indicators of right ventricular adaptation in pulmonary arterial hypertension (PAH) patients. The proposed research seeks to: 1) develop a multivariable model to identify clinically available metrics as...
This Project Grant award of $117,000 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to develop an analysis pipeline for three-dimensional echocardiographic (3DE) imaging of the right ventricle. The goal is to enhance the computational processing of 3D strain data using machine learning techniques, and to compare these 3D strain parameters to clinical outcomes for patients with pulmonary arterial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), with CFDA program title "Cardiovascular Diseases Research" (93.837), supports research focused on understanding the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The $522,794 award, with a period of performance from June 1, 2025 to March 31, 2029, will enable the University of Illinois to apply transgenic mouse models and complementary in vivo...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $760,708 Project Grant to The Methodist Hospital Research Institute in Houston, TX to investigate the role of alternative polyadenylation (APA) in right ventricular fibrosis associated with pulmonary hypertension. The research aims to elucidate the molecular mechanisms by which APA, specifically the regulation of the cleavage and polyadenylation specific factor 6...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $691,326 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Northwestern University to develop a "4D Right-Heart Virtual Catheter (VCATH)" technology. This innovative solution combines advanced mathematical modeling and 4D flow MRI to provide a comprehensive, non-invasive hemodynamic analysis of the right heart, enabling faster diagnosis, classification, and personalized prognosis of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $244,589 to The Research Foundation for the State University of New York (RF SUNY) to study the role of the VPS34 protein in pulmonary arterial hypertension (PAH). The research aims to examine the regulation and mechanisms of VPS34 activation in PAH, determine its impact on vascular smooth muscle cell proliferation and survival,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) in the amount of $498,000.00 will support research at the University of Florida to investigate the neuroimmune mechanisms contributing to the pathophysiology of pulmonary hypertension. The key objectives are to evaluate how microglia-dependent processes and the TREM2 receptor within the paraventricular nucleus of the hypothalamus impact sympathetic activation and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support research aimed at understanding the molecular mechanisms underlying pulmonary arterial hypertension (PAH) and identifying new therapeutic targets. The $658,885 award to the University of Missouri System will fund studies to determine how the protein factor Response Gene to Complement 32 (RGC-32) regulates the...
This federal Project Grant award, totaling $245,626, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a research project led by The Johns Hopkins University to validate lipidomic signatures associated with right ventricular and pulmonary vascular function in external cohorts of patients with or at risk for pulmonary vascular disease. The goal is to understand how aberrations in long-chain...
This $279,376 federal Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) will fund research to delineate and model the intra- and extra-cellular mechanisms contributing to right ventricular (RV) myocardial stiffening. The research will combine experimental micro-scale mechanical tests on cardiomyocytes and extracellular matrix samples, as well as computational modeling approaches to understand the role of stiffening mechanisms on RV diastolic function at...